Yale   

Does your approach differ across the HER2 IHC spectrum?

In the DAISY trial, ORR of 30.6% in T-DXd treated patients (n = 38) with HER2-null breast cancer

Based on CheckMate 577?Is DFS endpoint sufficient to establish SOC or is OS benefit needed?

Would you treat this as a locally advanced breast cancer and offer surgery, radiation, and systemic therapy? Does your management change depending on ...

Patient is young. Bilirubin normalizes when tucatinib is held, but again increases to grade 2 when it is restarted. Evaluation for hemolysis was negat...

Do you routinely offer post-operative adjuvant radiation in addition to chemotherapy? Are the results of the recently published negative phase II...

Which agents would you select and for how long would you treat them?

Patient underwent mastectomy for DCIS in the setting of previous lumpectomy and adjuvant radiation for the invasive breast cancer. 

Patient is ypT2N1

Is there any role for denosumab? How do you counsel patients regarding the benefit of bisphosphonates on breast cancer outcomes?

Ampullary carcinoma is not in the NCCN guidelines. Please address not only the role for therapy but the optimal regimen (i.e. Gem based, vs mFOLFIRINO...

I am considering every 6 week pembrolizumab dosing in patients >70 years old in whom I want to reduce clinic visits for, especially in the context ...

Is adjuvant radiation and/or adjuvant chemotherapy indicated? 

Would you use FOLFIRINOX as in Prodige 23 or FOLFOX as in RAPIDO?

For a patient with high risk disease and a severe enough reaction that additional taxane-based therapy is contraindicated, do you consider alternate c...

Is there an advantage to early diagnosis and intervention versus observation until the nodules are amenable to percutaneous biopsy?

Should staging and treatment decisions be made based on imaging alone?

If so, how long is too long to wait?

How, if any, do you utilize genomic testing to guide systemic therapy?

If so, what is your approach to sequencing and timing of targeted therapy and local therapy?

If so do you favor repeat tumor biopsy or cfDNA?

What if the patient has thymoma-associated myasthenia gravis?

How does the timing of recurrence play into your decision?

When would you favor delivering local therapy (e.g. SBRT) prior to systemic therapy?

These patients have been largely excluded from these trials.  What if the infection is well controlled?

Would you offer adjuvant TKI following ADAURA data?  Or proceed with durvalumab based on PACIFIC data?

Should fractionated EBRT be administered or can repeat SBRT be used?